Why PAH Remains a High-Unmet-Need Disease

Pulmonary arterial hypertension (PAH) is a progressive, life-threatening vasculopathy characterised by elevated pulmonary vascular resistance, right ventricular failure, and a 5-year survival rate of approximately 60% even with current treatment. Despite decades of approved therapies, the disease continues to kill the majority of patients within a decade of diagnosis — a statistic that frames every patent filing and clinical trial in this pipeline analysis.

The pathobiology of PAH extends well beyond simple vasoconstriction. Retrieved academic literature frames cellular proliferation, inflammation, and thrombosis as dominant pathobiologic processes, with chronic vasoconstriction playing a comparatively minor role. This distinction matters for drug development: it explains why vasodilator monotherapy has reached its ceiling and why the pipeline is now dominated by anti-remodeling biologics, combination regimens, and anti-proliferative small molecules.

At the molecular level, PAH is driven by progressive obliteration of small pulmonary arteries through smooth muscle cell (SMC) and endothelial cell (EC) proliferation, vascular remodeling, and neointima formation — ultimately causing right ventricular hypertrophy and failure. Key dysregulated axes include the ActRII/activin-BMP pathway, the prostacyclin (IP) receptor pathway, PDGF/PDGFRβ-mediated SMC proliferation, and the endothelin and NO/sGC pathways. According to WHO, pulmonary hypertension represents a growing global health burden, with PAH among its most severe subtypes.

Sotatercept: Clinical Evidence and the ActRII Patent Estate

Sotatercept is the most clinically advanced and most extensively patented agent in the PAH pipeline dataset, with Acceleron Pharma (now Merck Sharp & Dohme) having built at least nine distinct patent families across six continents between 2019 and 2025. The agent works by sequestering activin ligands through its ActRIIA-hFc fusion architecture, rebalancing the BMP/activin signalling axis to reduce pathological vascular remodeling — a mechanism entirely distinct from vasodilation.

The clearest clinical evidence signal in the dataset comes from a Canadian Acceleron patent (2021) that cites placebo-controlled trial data at 24 weeks. Sotatercept at 0.3 mg/kg reduced pulmonary vascular resistance (PVR) by −145.8 dyn·s/cm⁵ versus placebo; at 0.7 mg/kg, the reduction was −239.5 dyn·s/cm⁵. Both doses also produced improvements in 6-minute walk distance (6MWD), pulmonary artery systolic pressure (PASP), and NT-proBNP — a dose-dependent hemodynamic response profile consistent with the endpoint structure of the PULSAR and STELLAR trials referenced in the broader literature context.

“Sotatercept at 0.7 mg/kg reduced pulmonary vascular resistance by −239.5 dyn·s/cm⁵ versus placebo at 24 weeks — the most clinically substantive evidence signal in the entire PAH patent dataset analysed.”

Multiple Acceleron and MSD filings specify a dosing range of 0.1–2.0 mg/kg, with outcome endpoints including PVR reduction, 6MWD increase, NT-proBNP decrease, WHO functional class improvement, and right ventricular function improvement. The geographic breadth of this IP estate — AU, BR, CA, CN, CO, ID, JP, MX, US, and WO jurisdictions — creates a robust defensive perimeter that will be difficult for competitors to design around without targeting alternative mechanisms.

The mechanistic rationale for sotatercept’s efficacy is supported by INSERM research identifying overactivity of activin–Smad2/3 signalling in PAH vascular cells, with elevated activin A and follistatin-like 3 (FSTL3) confirmed as independent prognostic factors of PAH severity and mortality in the EFFORT PAH cohort — validated in an independent Imperial College London cohort. This biomarker evidence provides the biological scaffolding on which sotatercept’s clinical programme rests, and signals a future direction toward companion diagnostics for patient stratification in sotatercept trials.

Ralinepag and the Next Generation of IP Receptor Agonists

Ralinepag (APD811), developed by Arena Pharmaceuticals and United Therapeutics, is an oral, selective PGI2 receptor agonist that acts through the prostacyclin (IP) receptor to increase intracellular cAMP, producing vasodilation and antiproliferative effects. The pharmacological rationale is straightforward: prostacyclin levels are lower in PAH patients compared to healthy controls, and restoring IP receptor signalling addresses both vasoconstriction and pathological vascular proliferation.

What differentiates ralinepag from its predecessor selexipag is primarily pharmacokinetic. Patent specifications contrast ralinepag’s comparatively longer plasma half-life against selexipag and its active metabolite MRE-269, suggesting potential advantages in dosing convenience and patient adherence. An EP-active patent (2025) from inventor Lucie H. Clapp — linked to University College London — discloses that ralinepag combinations with riociguat, treprostinil, or iloprost achieve additive or synergistic clinical effects at reduced individual doses, with improved safety profiles versus monotherapy.

United Therapeutics’ 2024 Chinese pending patent covers ralinepag prodrug formulations for pulmonary hypertension diseases, signalling active formulation-stage development. An EP-active Arena Pharmaceuticals patent discloses ralinepag’s molecular scaffold and its utility across PAH subgroups including idiopathic, familial, connective tissue disease-associated, and CTEPH — indicating broad label ambitions beyond the core iPAH population.

Selexipag, the approved IP receptor agonist, appears in this dataset primarily as the third component of the initial triple combination regimen (macitentan + tadalafil + selexipag). Its established safety profile and regulatory approval make it the preferred IP agonist anchor for combination IP strategies — though ralinepag’s longer half-life positions it as a potential successor in future upfront combination trials. As noted by the European Medicines Agency, prostacyclin pathway agents remain a cornerstone of approved PAH pharmacotherapy.

Combination Regimens: Triple Therapy, FDCs, and Anti-Remodeling Pairs

The most pronounced structural shift in the PAH pipeline is the accelerating move toward upfront combination therapy as a default treatment paradigm. Retrieved patent data identifies at least five distinct combination clusters, each with its own IP architecture and clinical rationale.

Initial Oral Triple Combination: Macitentan + Tadalafil + Selexipag

The macitentan + tadalafil + selexipag regimen is the most extensively IP-protected combination in the dataset, with Actelion/Janssen and Japan Shinyaku filings across at least 10 jurisdictions including IL, ID, TW, CA, AU, BR, EP, JP, NZ, and CN. The therapeutic rationale — simultaneously targeting three pathways (endothelin via ERA, NO via PDE-5i, and prostacyclin via IP agonist) from treatment initiation — reflects ESC/ERS guideline evolution toward upfront combination for high-risk patients.

Patent specifications from Actelion/Japan Shinyaku define clinical enrollment criteria: mPAP ≥25 mmHg, PAWP ≤15 mmHg, and PVR ≥240 dyn·s/cm⁵, with a specific escalation schedule (macitentan + tadalafil on Day 1; selexipag added on Day 15 ±3 days). These specifications are consistent with the TRITON study design. Japan Shinyaku holds JP-active patents as a licensed partner, with active filings as of 2025.

Macitentan/Tadalafil Fixed-Dose Combination

Actelion’s 2025 CN-pending patent on a fixed-dose combination (FDC) tablet of macitentan + tadalafil addresses patient compliance in multi-pill regimens and defines clinical transition criteria from monotherapy. This formulation-stage development signals regulatory submission-oriented activity, building on the backbone of the triple combination regimen by simplifying the ERA + PDE-5i component into a single tablet.

Sotatercept + Seralutinib: The Next Competitive Frontier

The most recently filed, mechanistically novel combination in the dataset comes from GB002, Inc., which has filed patents in AU (2025), JP (2025), CN (2025), and US (2026) on the combination of seralutinib — a selective PDGFR/FGFR/CSF1R inhibitor — with sotatercept. The rationale is mechanistically complementary: sotatercept addresses the activin/BMP imbalance driving vascular remodeling, while seralutinib targets PDGFR-mediated SMC proliferation. Neither mechanism is primarily vasodilatory, representing a potential disease-modifying strategy for PAH.

Emerging Targets and Anti-Proliferative Strategies

Beyond the leading clinical programmes, the PAH pipeline contains a layer of earlier-stage anti-proliferative and pathway-targeted agents that address the vascular remodeling biology of PAH through distinct mechanisms — none of which are primarily vasodilatory.

CDK Inhibition: Palbociclib (Pfizer)

Pfizer has filed patents across SG, TW, MX, and JP jurisdictions proposing the CDK inhibitor palbociclib as an antiproliferative agent for PAH. The mechanism — cell-cycle arrest in pulmonary artery smooth muscle cells (PASMC) — is designed to reverse progressive vascular obliteration rather than dilate existing vessels. These filings are characterised as primarily preclinical-stage claims, with limited clinical data density relative to the sotatercept or triple combination clusters.

Tryptophan Hydroxylase Inhibition: Rodatristat (Altavant Sciences)

Altavant Sciences/Roivant Sciences has filed multiple WO, AU, US, CA, and JP patents (2021–2023) on rodatristat ethyl, a tryptophan hydroxylase inhibitor that targets serotonin biosynthesis as a pro-proliferative pathway in PAH. Combination filings cover rodatristat with ambrisentan, sildenafil, tadalafil, bosentan, treprostinil, selexipag, and macitentan. Notably, patent specifications reference a Cmax,unbound threshold of <0.028 µM as a drug-drug interaction safety criterion for combination regimens — indicating that clinical pharmacokinetic data has already informed the patent claims.

PARP-1 Inhibition and PDGFR Biologics

Université Laval/Bonnet has filed WO patents on PARP-1 inhibitors for PAH, supported by animal model evidence (monocrotaline and Sugen rat models) demonstrating reduction in medial wall thickness and improved pulmonary artery acceleration time. Separately, Regeneron Pharmaceuticals has filed a JP-pending patent (2024) on an anti-PDGF-B antibody for PAH, noting that PDGFA, PDGFB, PDGFRα, and PDGFRβ are upregulated in iPAH patient lung small arteries and confirmed by Western blot. According to NIH, PDGF signalling is an established driver of vascular smooth muscle proliferation across multiple disease contexts.

Novel Mechanistic Targets: Hic-5/SMAD7, MicroRNA-130/301, and RAGE/STAT3

Academic institutions are driving discovery of additional intervention points. A pending Chinese patent from Fuwai Hospital (National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences) identifies Hic-5/SMAD7 interactions as a novel target, proposing that disrupting Hic-5’s sequestration of SMAD7 restores anti-proliferative Smad signalling. Brigham and Women’s Hospital has filed on the microRNA-130/301 family as a regulatory node in PAH biology. These represent the earliest-stage signals in the dataset, with the highest technical and regulatory risk for developers evaluating these programmes. Research published by Nature has highlighted microRNA dysregulation as an emerging frontier in pulmonary vascular disease biology.

Strategic Implications for Drug Developers and IP Teams

The PAH patent landscape reveals a field in strategic transition: from single-pathway vasodilator IP toward multi-mechanism combination estates and anti-remodeling biologics. For drug developers and IP teams, several actionable signals emerge from this dataset.

Sotatercept represents a platform IP opportunity. The explicit clinical hemodynamic data embedded in Acceleron/MSD patent specifications — PVR reductions, 6MWD improvements, NT-proBNP decreases — establishes evidentiary anchors that will support label claims. Competitors seeking to develop alternative ActRII-targeting agents must navigate this dense multinational estate or target alternative ligands within the BMP/activin axis.

Triple combination regimen IP is consolidating around Actelion/Janssen and Japan Shinyaku. With active JP patents (2025) and pending filings across multiple jurisdictions for the macitentan + tadalafil + selexipag regimen, companies seeking to develop analogous upfront triple therapies using alternative agents — such as ambrisentan + tadalafil + ralinepag — should carefully design around this IP cluster or pursue distinct dosing schedules and patient populations.

The ralinepag + riociguat combination carries European IP risk. The EP-active Clapp patent (2025) on ralinepag combined with riociguat, treprostinil, or iloprost could create IP tension with sGC stimulator-focused combination strategies. Drug developers working on dual prostacyclin + sGC pathway approaches should evaluate freedom-to-operate carefully in European jurisdictions, as assessed against standards from bodies such as the European Patent Office.

Anti-proliferative and pathway-targeted agents remain in preclinical IP territory. Pfizer’s palbociclib filings, Altavant’s rodatristat, and Université Laval’s PARP-1 inhibitor patents lack the clinical data density of the sotatercept or triple combination IP clusters, indicating earlier development stages and greater technical and regulatory risk for investors and drug developers evaluating these programmes.

Biomarker-guided patient stratification is becoming an IP category in its own right. The INSERM EFFORT cohort patents (2024) on activin A/FSTL3 and β-NGF/CXCL9/TRAIL panels signal a direction toward precision patient selection — potentially enabling enriched enrollment in sotatercept combination trials and representing a companion diagnostic opportunity aligned with the broader trend toward precision medicine IP strategy in life sciences.

“The sotatercept + seralutinib combination represents a potential disease-modifying strategy for PAH — two distinct anti-remodeling mechanisms, neither of which is primarily vasodilatory, targeting the 60% 5-year survival rate that current therapy has failed to improve substantially.”

For IP teams, the practical implication is that the PAH space is bifurcating: a mature, densely protected vasodilator combination space dominated by Actelion/Janssen, and an emerging anti-remodeling space where the IP landscape remains more navigable — but is filling rapidly, particularly around sotatercept combinations. Monitoring new filings from GB002, Acceleron/MSD, and INSERM through a platform such as PatSnap’s innovation intelligence platform will be essential for maintaining competitive awareness in this rapidly evolving field.